Back to top
more

AcelRx Pharmaceuticals, Inc. (ACRX)

(Delayed Data from NSDQ)

$3.66 USD

3.66
1,585,684

+0.10 (2.81%)

Updated May 3, 2019 04:00 PM ET

After-Market: $3.65 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

AcelRx Pharmaceuticals (ACRX) Upgraded to Buy: Here's Why

AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Lags Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 26.09% and -68.64%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for AcelRx (ACRX) This Earnings Season?

We expect AcelRx (ACRX) to provide update on the launch of its newly approved drug DSUVIA, when it reports first-quarter 2019 results.

Will AcelRx Pharmaceuticals (ACRX) Report Negative Earnings Next Week? What You Should Know

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kinjel Shah headshot

Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy

Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.

AcelRx Pharmaceuticals (ACRX) Upgraded to Buy: What Does It Mean for the Stock?

AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Here's Why Momentum Investors Will Love AcelRx Pharmaceuticals (ACRX)

Does AcelRx Pharmaceuticals (ACRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Is AcelRx Pharmaceuticals (ACRX) Outperforming Other Medical Stocks This Year?

Is (ACRX) Outperforming Other Medical Stocks This Year?

Implied Volatility Surging for AcelRx Pharmaceuticals (ACRX) Stock Options

Investors need to pay close attention to AcelRx Pharmaceuticals (ACRX) stock based on the movements in the options market lately.

AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -5.00% and -65.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Will AcelRx Pharmaceuticals (ACRX) Report Negative Earnings Next Week? What You Should Know

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Options Traders Betting on a Big Move in AcelRx Pharmaceuticals (ACRX) Stock?

Investors need to pay close attention to AcelRx Pharmaceuticals (ACRX) stock based on the movements in the options market lately.

AcelRx's Dsuvia Gets FDA Committee Approval, Shares Rally

AcelRx (ACRX) earns majority votes from an FDA advisory committee, which recommends approval of Dsuvia for treating moderate-to-severe acute pain in adult patients.

Are Options Traders Betting on a Big Move in AcelRx Pharmaceuticals (ACRX) Stock?

Investors need to pay close attention to AcelRx Pharmaceuticals (ACRX) stock based on the movements in the options market lately.

    Is AcelRx Pharmaceuticals (ACRX) Outperforming Other Medical Stocks This Year?

    Is (ACRX) Outperforming Other Medical Stocks This Year?

      AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates

      AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -5.26% and -11.57%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

        CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA

        CTI BioPharma (CTIC) conducts Type B meeting with the FDA to discuss a regulatory pathway for its lead pipeline candidate Pacritinib, currently under study for the treatment of myelofibrosis.

          Pacira (PCRX) Issues Strong Preliminary Exparel Sales for Q2

          Pacira (PCRX) announces robust preliminary results for Exparel sales in second quarter on the back of increasing adoption for pain management in surgical procedures.

            VIVUS' PAH Candidate Data Positive in Early Stage Study

            VIVUS' (VVUS) pipeline candidate, VI-0106, shows positive activity in a preliminary analysis of phase I study in patients with pulmonary arterial hypertension.

              Aclaris' Alopecia Candidate Gets Fast Track Designation

              The FDA grants fast track status to Aclaris' (ACRS) JAK-inhibitor, ATI-502, for the treatment of alopecia areata.

                Top Ranked Momentum Stocks to Buy for June 25th

                Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 25th:

                  Shire (SHPG) HAE Drug Gets FDA Nod for Pediatric Population

                  Shire (SHPG) gains FDA approval for expanding the label of its hereditary angioedema (HAE) drug, Cinryze, to include its usage among pediatric patients aged six years and older.

                    Kinjel Shah headshot

                    Small Drugmakers Edging Out the Bigshots: 7 Stocks to Buy

                    Smaller drugmakers are having a relatively better year than their larger counterparts. Here are seven stocks to buy.

                      Top Ranked Momentum Stocks to Buy for June 15th

                      Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 15th:

                        Top Ranked Momentum Stocks to Buy for June 8th

                        Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 8th: